Related Experiment Video

Updated: Jun 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant

Ahmed Ashour Ahmed1, Juliet Goldsmith, Izabela Fokt

  • 1Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 422, Houston, TX 77030, USA.

Cancer Chemotherapy and Pharmacology
|February 23, 2011
PubMed
Abstract

Insights

ITB-301, a novel genistein derivative, effectively inhibits ovarian cancer cell proliferation by disrupting microtubules and causing mitotic arrest. This compound shows promise against multidrug-resistant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Genistein, a soy isoflavone, exhibits anti-tumor properties but suffers from poor solubility and efficacy.
  • Chemical modifications aim to enhance genistein's therapeutic potential for cancer treatment.

Purpose of the Study:

  • To elucidate the anti-tumor mechanism of ITB-301, a novel genistein glycoside.
  • To evaluate ITB-301's efficacy in various cancer cell lines, including multidrug-resistant models.

Main Methods:

  • ITB-301 synthesized and characterized.
  • Cancer cell proliferation assays, cell cycle analysis, immunofluorescence, and microscopy employed.
  • siRNA-mediated BUBR1 depletion and drug resistance models used to assess mechanism.

Main Results:

  • ITB-301 significantly inhibited proliferation of ovarian cancer cells (SKOv3) with a 50% growth inhibitory concentration of 0.5 μM.
  • ITB-301 induced dose- and time-dependent microtubule depolymerization, leading to mitotic arrest.
  • Cytotoxic effects were dependent on mitotic arrest induction and unaffected by efflux-mediated drug resistance.

Conclusions:

  • ITB-301 is identified as a novel anti-tubulin agent with potent anti-cancer activity.
  • The compound demonstrates potential for treating multidrug-resistant cancers.
  • A structural model for ITB-301 binding to tubulin dimers was proposed, guiding future analog design.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...